Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

The Timing for Liraglutide in Patients Remaining Obese at 6 Months After Metabolic Surgery: an Observational Study

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are:

[primary hypothesis 1] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery.

[primary hypothesis 2] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Inclusion Criteria:

• Patients 6 months after metabolic surgery;
• 18 years ≤ age ≤ 65 years;
• Body Mass Index (BMI) ≥ 28 kg/m^2

Exclusion Criteria:

• allergy to liraglutide, severe hepatic or renal impairment (eGFR <60 mL/min/1.73 m² or ALT/AST ≥3× ULN)
• history of medullary thyroid carcinoma, MEN-2 or other malignancies
• pancreatitis or severe gastrointestinal disease, pregnancy or lactation
• use of anti-obesity drugs or other interventional trials within 3 months or major uncontrolled illness
• Patients were discontinued if withdrawn, intolerant, lost to follow-up, or developed severe adverse events.